Fig. 2

Glucocorticoid agonists increase retinal stem and progenitor cell proliferation through glucocorticoid receptor and mineralocorticoid receptor signaling in mice. a–c Quantification of growth parameters for RSPCs at day 2, day 4, and day 6 of a monolayer growth assay. *Significantly different from control within that time point. a The proportion of live cells was not significantly different across drug treatments (p = 0.55), and there was no interaction between drug and time (p = 0.99). There was a significant effect of time on the proportion of live cells, and all times were significantly different (two-way ANOVA F (_{2, 195}) = 261.9, p < 0.001; Holm-Sidak post hoc test, *p < 0.05). N = 6 for all conditions at each time point. b The proportion of proliferating EdU-labeled cells relative to control. There was a significant interaction between drug and time (two-way ANOVA F (_{24, 195}) = 2.59, p < 0.001; Holm-Sidak post hoc test, *p < 0.05). N = 6 for all conditions at each time point. c The total number of cells relative to control. There was a significant interaction between drug and time (two-way ANOVA F (_{24, 429}) = 3.79, p < 0.001; Holm-Sidak post hoc test, *p < 0.05). N = 12 for all conditions at each time point. d Total RSPC number at the end of a 7-day monolayer growth assay with 0.1% DMSO and 0.1% EtOH in all conditions. Control was significantly different from all Dex treatment conditions but not spironolactone (Spiro) or RU486 alone (one-way ANOVA F (_{5, 12}) = 67.88, p < 0.001; Holm-Sidak post hoc test, *p < 0.05). N = 3 for RU486 alone. N = 4 for all other groups. Data are mean ± SEM